Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals Inc. | INO-4800 - (INNOVATE) | COVID-19 vaccine | Phase 2/3 | Trial Discontinued | Intramuscular | COVID-19 |
| Inovio Pharmaceuticals Inc. | INO-3112 and LOQTORZI (toripalimab-tpzi) | HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC) | Phase 3 | Trial Planned | INO-3112 intramuscular LOQTORZI intravenous | Oncology |
| Inovio Pharmaceuticals Inc. | INO-3107 | HPV 6 and HPV 11-associated Recurrent respiratory papillomatosis | PDUFA | Ongoing | Intramuscular | Respiratory |
| Inovio Pharmaceuticals Inc. | VGX-3100 | Human papilloma virus (HPV)-related anal dysplasia | Phase 2 | Trial Completed | Intramuscular | Oncology |
| Inovio Pharmaceuticals Inc. | PENNVAX-GP | HIV | Phase 2 | Trial Completed | Intramuscular | Anti-HIV |
| Inovio Pharmaceuticals Inc. | INO-4700 / GLS-5300 | MERS virus (Middle East Respiratory Syndrome) | Phase 2 | Trial Discontinued | Intramuscular | Respiratory |
| Insmed Incorporated | Brensocatib | Cystic Fibrosis (CF) | Phase 2 | Data Released | Oral | Respiratory |
| Insmed Incorporated | ARIKAYCE - (ENCORE) | Newly Diagnosed or Recurrent MAC Lung Disease | Phase 3 | Enrollment Conclusion | Inhalation | Respiratory |
